ICOS Corporation Withdraws Shelf Registration Statement
Tuesday June 17, 6:30 pm ET
BOTHELL, Wash.--(BUSINESS WIRE)--June 17, 2003--ICOS Corporation (Nasdaq:ICOS - News) announced today that it has made a request to the Securities and Exchange Commission to withdraw the universal shelf registration statement on Form S-3 that was filed on May 27, 2003. ICOS no longer plans to pursue a financing under that universal shelf registration statement following the pricing of a private offering of convertible subordinated notes on June 16, 2003.
ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products expected to have significant commercial potential. ICOS applies its integrated approach to erectile dysfunction and other urologic disorders, sepsis and inflammatory diseases. ICOS' strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing ICOS' opportunities to market breakthrough products.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause ICOS' results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims and litigation and other risks detailed in ICOS' latest Annual Report on Form 10-K and its other SEC filings.
--------------------------------------------------------------------------------
Contact:
ICOS Corporation
Lacy Fitzpatrick, 425/415-2207
--------------------------------------------------------------------------------
Source: ICOS Corporation |
